Literature DB >> 20587763

Depressive symptoms in pulmonary arterial hypertension: prevalence and association with functional status.

Deborah H McCollister1, Michelle Beutz, Vallerie McLaughlin, John Rumsfeld, Frederick A Masoudi, Mark Tripputi, Thomas Yaeger, Philippe Weintraub, David B Badesch.   

Abstract

BACKGROUND: In patients with left-heart disease, depressive symptoms have a significant impact on functional status and quality of life. The prevalence of depressive symptoms, and their impact on patients with pulmonary arterial hypertension (PAH) is understudied.
OBJECTIVE: The authors investigated the prevalence of depressive symptoms in PAH and their correlation with physical functioning.
METHOD: Consecutive outpatients with PAH (idiopathic; or associated with scleroderma, congenital heart disease, or anorexiant use) seen in two university PAH clinics were screened. At two outpatient visits, 8 to 16 weeks apart, patients completed the PHQ-8, a well-validated instrument for grading severity of depressive symptoms; they were assessed for cardiac functional class (FC), and performed a 6-minute walk-distance test (6MWD).
RESULTS: A group of 100 patients (88% women, 50% with idiopathic PAH) were enrolled. At baseline, 15% of subjects had symptoms suggestive of major depressive disorder; 40% had mild-to-moderate depressive symptoms; and 45% had no-to-minimal depressive symptoms.
CONCLUSION: Depression is common in patients with PAH, with 55% demonstrating depressive symptoms. These results suggest that screening patients with PAH will identify a large proportion of patients who might benefit from depression therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20587763     DOI: 10.1176/appi.psy.51.4.339

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  31 in total

1.  Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Authors:  Colm McCabe; Maxine Bennett; Natalie Doughty; Robert MacKenzie Ross; Linda Sharples; Joanna Pepke-Zaba
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

2.  Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension.

Authors:  Ali Sadoughi; Kari E Roberts; Ioana R Preston; Ginny P Lai; Deborah H McCollister; Harrison W Farber; Nicholas S Hill
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

3.  Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided.

Authors:  Andrea Huppertz; Lars Werntz; Andreas D Meid; Kathrin I Foerster; Jürgen Burhenne; David Czock; Gerd Mikus; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2018-10-11       Impact factor: 4.335

4.  Interleukin-6 and tumor necrosis factor-α are associated with quality of life-related symptoms in pulmonary arterial hypertension.

Authors:  Lea Ann Matura; Corey E Ventetuolo; Harold I Palevsky; David J Lederer; Evelyn M Horn; Stephen C Mathai; Diane Pinder; Christine Archer-Chicko; Emilia Bagiella; Kari E Roberts; Russell P Tracy; Paul M Hassoun; Reda E Girgis; Steven M Kawut
Journal:  Ann Am Thorac Soc       Date:  2015-03

Review 5.  Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension.

Authors:  Shuyan Gu; Huimei Hu; Hengjin Dong
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

6.  Exercise capacity affects quality of life in patients with pulmonary hypertension.

Authors:  Michael Halank; Franziska Einsle; Stephanie Lehman; Hinrich Bremer; Ralf Ewert; Heinrike Wilkens; F Joachim Meyer; Ekkehard Grünig; Hans-Jürgen Seyfarth; Martin Kolditz; Gesine Wieder; Gert Höffken; Volker Köllner
Journal:  Lung       Date:  2013-05-17       Impact factor: 2.584

7.  Symptom Interference Severity and Health-Related Quality of Life in Pulmonary Arterial Hypertension.

Authors:  Lea Ann Matura; Annette McDonough; Diane L Carroll
Journal:  J Pain Symptom Manage       Date:  2015-08-20       Impact factor: 3.612

8.  Anxiety, Depression, and Health-Related QOL in Patients Diagnosed with PAH or CTEPH.

Authors:  Elena Pfeuffer; Holger Krannich; Michael Halank; Heinrike Wilkens; Philipp Kolb; Berthold Jany; Matthias Held
Journal:  Lung       Date:  2017-10-09       Impact factor: 2.584

Review 9.  Exercise training in pulmonary arterial hypertension.

Authors:  Laura Adelaide Dalla Vecchia; Maurizio Bussotti
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

10.  Progressive muscle relaxation improves anxiety and depression of pulmonary arterial hypertension patients.

Authors:  Yunping Li; Ranran Wang; Jingqun Tang; Chen Chen; Ling Tan; Zhongshi Wu; Fenglei Yu; Xiang Wang
Journal:  Evid Based Complement Alternat Med       Date:  2015-04-01       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.